Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors.
Caocci G, Mulas O, Annunziata M, Luciano L, Abruzzese E, Bonifacio M, Orlandi EM, Albano F, Galimberti S, Iurlo A, Pregno P, Sgherza N, Martino B, Binotto G, Castagnetti F, Gozzini A, Bocchia M, Fozza C, Stagno F, Simula MP, De Gregorio F, Trawinska MM, Scaffidi L, Elena C, Attolico I, Baratè C, Cattaneo D, Pirillo F, Gugliotta G, Sicuranza A, Molica M, La Nasa G, Foà R, Breccia M. Caocci G, et al. Among authors: attolico i. Int J Cardiol. 2020 Feb 15;301:163-166. doi: 10.1016/j.ijcard.2019.10.036. Epub 2019 Oct 24. Int J Cardiol. 2020. PMID: 31711851
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors.
Mulas O, Caocci G, Stagno F, Bonifacio M, Annunziata M, Luciano L, Orlandi EM, Abruzzese E, Sgherza N, Martino B, Albano F, Galimberti S, Pregno P, Bocchia M, Castagnetti F, Tiribelli M, Binotto G, Gozzini A, Capodanno I, Fozza C, Luzi D, Efficace F, Simula MP, Scaffidi L, De Gregorio F, Elena C, Trawinska MM, Cattaneo D, Attolico I, Baratè C, Pirillo F, Sicuranza A, Gugliotta G, Stella R, Scalzulli E, Iurlo A, Foà R, Breccia M, La Nasa G. Mulas O, et al. Among authors: attolico i. Ann Hematol. 2020 Jul;99(7):1525-1530. doi: 10.1007/s00277-020-04102-6. Epub 2020 May 30. Ann Hematol. 2020. PMID: 32474619
Low-dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previous TKIs.
Iurlo A, Cattaneo D, Malato A, Accurso V, Annunziata M, Gozzini A, Scortechini AR, Bucelli C, Scalzulli E, Attolico I, Maggi A, Martino B, Caocci G, Abruzzese E, Pregno P, Luciano L, Breccia M. Iurlo A, et al. Among authors: attolico i. Am J Hematol. 2020 Oct;95(10):E260-E263. doi: 10.1002/ajh.25908. Epub 2020 Jul 7. Am J Hematol. 2020. PMID: 32557788 Free article. No abstract available.
Favorable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib.
Mulas O, Caocci G, Annunziata M, Martino B, Luciano L, Castagnetti F, Pregno P, Galimberti S, Albano F, Orlandi EM, Sgherza N, Iurlo A, Bonifacio M, Binotto G, Gozzini A, Bocchia M, Abruzzese E, Fozza C, Simula MP, De Gregorio F, Gugliotta G, Pirillo F, Baratè C, Attolico I, Elena C, Cattaneo D, Scaffidi L, Sicuranza A, Trawinska MM, Scalzulli E, Foà R, Breccia M, La Nasa G. Mulas O, et al. Among authors: attolico i. Hematol Oncol. 2020 Oct;38(4):607-610. doi: 10.1002/hon.2765. Epub 2020 Jul 23. Hematol Oncol. 2020. PMID: 32602167 No abstract available.
Choice of Frontline Tyrosine-Kinase Inhibitor and Early Events in Very Elderly Patients With Chronic Myeloid Leukemia in Chronic Phase: A "Campus CML" Study.
Bucelli C, Capodanno I, Miggiano MC, Cavazzini F, Crescenzi SL, Russo S, Carmosino I, Annunziata M, Sorà F, Bonifacio M, Luciano L, Caocci G, Loglisci G, Elena C, Lunghi F, Mullai R, Attolico I, Binotto G, Crisà E, Sportoletti P, Di Veroli A, Scortechini AR, Leporace AP, Maggi A, Crugnola M, Stagno F, Sancetta R, Murgano P, Rapezzi D, Luzi D, Vincelli DI, Galimberti S, Bocchia M, Fava C, Malato A, Abruzzese E, Saglio G, Specchia G, Breccia M, Iurlo A, Tiribelli M, Latagliata R. Bucelli C, et al. Among authors: attolico i. Eur J Haematol. 2025 Jan;114(1):37-44. doi: 10.1111/ejh.14299. Epub 2024 Sep 12. Eur J Haematol. 2025. PMID: 39263855 Free PMC article.
Effects of daratumumab on hematopoietic stem cell collection and engraftment in multiple myeloma patients eligible for autologous transplantation: results of the real-life PRIMULA study comparing bortezomib, thalidomide and dexamethasone (VTd) with VTd plus daratumumab (D-VTd) as induction therapy.
Strafella V, Attolico I, Carluccio P, Tarantini F, Curci P, Sgherza N, Rizzi R, Ostuni A, Buda G, Del Giudice ML, Marasco V, Mele A, Margiotta-Casaluci G, Valli VB, Mele G, Germano CR, Quinto AM, Palazzo G, Febbo MA, Ciuffreda L, Reddiconto G, Di Renzo N, Cimminiello M, Albano F, Musto P. Strafella V, et al. Among authors: attolico i. Ann Hematol. 2024 Oct;103(10):4345-4347. doi: 10.1007/s00277-024-05933-3. Epub 2024 Aug 22. Ann Hematol. 2024. PMID: 39168910 No abstract available.
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib.
Mulas O, Abruzzese E, Luciano L, Iurlo A, Attolico I, Castagnetti F, Galimberti S, Bonifacio M, Annunziata M, Gozzini A, Orlandi EM, Stagno F, Binotto G, Pregno P, Fozza C, Loi M, Trawinska MM, De Gregorio F, Cattaneo D, Albano F, Iezza M, Baratè C, Scaffidi L, Elena C, Giai V, Scalzulli E, Breccia M, La Nasa G, Caocci G. Mulas O, et al. Among authors: attolico i. Ann Hematol. 2024 Feb;103(2):427-436. doi: 10.1007/s00277-023-05556-0. Epub 2023 Nov 28. Ann Hematol. 2024. PMID: 38012435 Free PMC article.
TNFRSF13B gene mutation in familial acute myeloid leukemia: A new piece in the complex scenario of hereditary predisposition?
Cumbo C, Orsini P, Tarantini F, Anelli L, Zagaria A, Tragni V, Coccaro N, Tota G, Parciante E, Conserva MR, Redavid I, Minervini CF, Minervini A, Attolico I, Gentile M, Pierri CL, Specchia G, Musto P, Albano F. Cumbo C, et al. Among authors: attolico i. Hematol Oncol. 2023 Dec;41(5):942-946. doi: 10.1002/hon.3212. Epub 2023 Aug 3. Hematol Oncol. 2023. PMID: 37534633
Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML.
Tiribelli M, Latagliata R, Breccia M, Capodanno I, Miggiano MC, Cavazzini F, Bucelli C, Attolico I, Crescenzi SL, Russo S, Annunziata M, Sorà F, Bonifacio M, Mulas O, Loglisci G, Maggi A, Binotto G, Crisà E, Scortechini AR, Leporace AP, Sancetta R, Murgano P, Abruzzese E, Stagno F, Rapezzi D, Luzi D, Vincelli I, Bocchia M, Fava C, Malato A, Crugnola M, Pizzuti M, Lunghi F, Galimberti S, Dalmazzo M, Fanin R, Scalzulli E, Foà R, Iurlo A, Saglio G, Specchia G. Tiribelli M, et al. Among authors: attolico i. Cancer. 2023 Sep 1;129(17):2637-2644. doi: 10.1002/cncr.34923. Epub 2023 Jun 24. Cancer. 2023. PMID: 37354090 Free article.
44 results